New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
08:34 EDTLGND, GSKLigand partner GSK announces start of Phase 3 Eltrombopag study
Ligand Pharmaceuticals Incorporated (LGND) announces that its partner GlaxoSmithKline (GSK) has started a Phase 3 study to evaluate the platelet supportive care effects of eltrombopag in combination with azacitidine versus placebo in combination with azacitidine in intermediate-1, intermediate-2 or high-risk patients with myelodysplastic syndromes. The global SUPPORT study will assess the proportion of patients who are platelet transfusion free during the first four cycles of treatment.
News For LGND;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
07:37 EDTGSKPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
07:46 EDTGSKDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
May 19, 2015
09:25 EDTGSKGlaxoSmithKline asthma drug overused, risks underappreciated, ProPublica says
Subscribe for More Information
06:55 EDTGSKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 15, 2015
15:11 EDTGSKGlaxoSmithKline reports 16.12% stake in HTG Molecular
Subscribe for More Information
09:31 EDTGSKAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 13, 2015
11:38 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at UBS
Subscribe for More Information
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
May 12, 2015
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
May 11, 2015
15:54 EDTGSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change, reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be no logic in a split at this early time after the Novartis deal, the report added. Reference Link
11:31 EDTLGNDLigand price target raised to $127 from $116 at Roth Capital
Roth Capital raised its price target for Ligand Pharmaceuticals to $127 citing pipeline expansion following the company's Q1 results. Roth recommends "steady accumulation" of the stock and keeps a Buy rating on the name.
08:35 EDTLGNDLigand sees Q2 adjusted EPS 37c-40c, consensus 35c
Subscribe for More Information
08:34 EDTLGNDLigand affirms FY15 adjusted EPS view $2.14-$2.18, consensus $2.13
Subscribe for More Information
08:34 EDTLGNDLigand reports Q1 adjusted EPS 33c, consensus 27c
Reports Q1 revenue $14.6M, consensus $13.53M.
08:16 EDTLGNDLigand acquires rights to over 15 fully-funded development programs from Selexis
Subscribe for More Information
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use